In this study, the CRF1 antagonist, relative to placebo, significantly reduced the blood oxygen level-dependent signal in the hypothalamus in IBS patients with average or high levels of anxiety during expectation of abdominal pain. Here, CRHR1 is linked to irritable bowel syndrome.